casE rEport
A 27-year-old HIV-positive female was found to have hypertension, proteinuria, and elevated creatinine in 2014. A native kidney biopsy was done which was reported as focal segmental glomerulosclerosis. She rapidly progressed to end-stage renal disease in the next 2 years. She initiated hemodialysis through a right internal jugular vein-tunneled cuffed catheter, but after 2 months switched on to continuous ambulatory peritoneal dialysis (CAPD). She was not comfortable with CAPD and hence presented to us for kidney transplant.
On evaluation, she was found to be suitable for transplant. The CD4 cell count was 267/µL and HIV viral load was <20 copies. She was receiving raltegravir 400 mg twice a day, abacavir 300 mg twice a day, and lamivudine 50 mg once a day for her HIV positivity.
The only available donor from the family was her 53-year-old father who on medical evaluation was suitable but whose blood group was B+ (recipient A+). A swap transplant was suggested.
However, since the medicolegal formalities required for a swap transplant would have taken long time, [1] the family requested an ABOi transplant.
Her anti-B IgG and IgM titers were 1:64. Our standard desensitization protocol for ABOi transplant includes rituximab 200 mg on day -7 and day 0 and plasmapheresis and/or immunoadsorption to achieve antiblood group antibody titers <1:16. [2] This was modified in her case. She was given only single dose of rituximab 200 mg on day -7 to minimize the risk of intense immunosuppression. She received one session of plasmapheresis and after this her anti-B IgG and IgM titers were 1:8 preoperatively.
She underwent an ABOi living donor kidney transplant on July 26, 2016. She was given no induction treatment because of her HIV positivity. Further, in the Indian setting, basiliximab has not been shown to improve outcome even in poorly matched (defined as less than haplo match) ABOc living-related donor transplants. [3] Her maintenance immunosuppression included tapering doses of steroids, mycophenolate sodium, and tacrolimus. The target tacrolimus level was between 5 and 10 ng/ml. She had an uneventful posttransplant course and she was discharged with a serum creatinine of 0.78 mg%. On discharge, she was also started on valganciclovir and cotrimoxazole prophylaxis. Her highly active antiretroviral therapy included lamivudine (100 mg/day), abacavir (600 mg/ day), and raltegravir (800 mg/day) which do not interact with mycophenolate mofetil or tacrolimus.
A few days after discharge, she developed diarrhea for which mycophenolate was changed to azathioprine (2 mg/kg once a day) which also does not interact with the HIV drugs she was on. A month after transplant, she developed leukopenia and her azathioprine was stopped.
She is now >12 months posttransplant with stable graft function. She is on dual immunosuppression (tacrolimus and prednisolone) and lamivudine 100 mg, abacavir 600 mg, and raltegravir 800 mg/day for her HIV positivity.
discussion
HIV infection was once considered a contraindication to renal transplantation due to the potential risks of chronic immunosuppression exacerbating HIV-related immune dysfunction. However, advances in antiretroviral therapy led to pilot trials of kidney transplantation in HIV-positive individuals and that demonstrated acceptable results. The growing literature indicates that HIV-infected patients can be transplanted safely and enjoy posttransplant outcomes comparable to their uninfected counterparts.
A comprehensive review and meta-analysis of 12 series by Luis Landin concluded that kidney transplantation appears to be safe in patients undergoing HAART. [4] There are, however, a few problems in these cases. The risk of acute rejection is higher. [5, 6] The higher rates of rejection could be due to the interaction with some antiretroviral drugs. For example, nonnucleoside reverse transcriptase inhibitor administration may result in subtherapeutic levels of immunosuppressive drugs. Gruber et al. [7] however did not observe higher rejection rates. There can also be a problem of nephrotoxicity. Protease inhibitors may lead to toxic supratherapeutic levels of calcineurin inhibitors and mammalian target of rapamycin inhibitors. [8] Finally, HIV infection of the allograft may also contribute to allograft loss. [9] Like HIV positivity, ABO incompatibility was also at one time considered an absolute contraindication for kidney transplant. With desensitization methods achieving adequate anti-blood group antibody reduction before transplant, results of ABOi transplant are now comparable to those of ABOc kidney transplants. [10] An Indian study by Jha et al. [11] also showed that graft and patient survival was at par with ABOc ones.
The main concern about performing ABOi kidney transplant in an HIV-positive patient is that aggressive preoperative immunosuppression for desensitization can exacerbate HIV-related immune dysfunction and increase the risk of infection. Campara et al. [12] were the first to report ABOi renal transplantation in a 47-year-old African-American man with HIV positivity. They used standard protocol (interleukin-2 receptor antagonist induction along with tacrolimus and mycophenolate mofetil maintenance) after desensitization to reduce antiblood group antibody titers before transplant. We modified our protocol to reduce the risk of severe immunosuppression. We used only one dose of rituximab 200 mg on day 7 (instead of two doses) as part of desensitization protocol and we used no induction agent.
To our knowledge, this is only the second report in the world and first in India of ABOi kidney transplant in an HIV-positive patient.
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